Clinical Efficacy and Central Neuroimaging Mechanisms of Acupuncture as an Adjunctive Treatment for Tapering Benzodiazepine Receptor Agonists in Patients with Chronic Insomnia Disorder

注册号:

Registration number:

ITMCTR2025000942

最近更新日期:

Date of Last Refreshed on:

2025-05-09

注册时间:

Date of Registration:

2025-05-09

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺对慢性失眠患者辅助减停苯二氮卓受体激动剂的临床疗效及中枢影像学机制研究

Public title:

Clinical Efficacy and Central Neuroimaging Mechanisms of Acupuncture as an Adjunctive Treatment for Tapering Benzodiazepine Receptor Agonists in Patients with Chronic Insomnia Disorder

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺对慢性失眠患者辅助减停苯二氮卓受体激动剂的临床疗效及中枢影像学机制研究

Scientific title:

Clinical Efficacy and Central Neuroimaging Mechanisms of Acupuncture as an Adjunctive Treatment for Tapering Benzodiazepine Receptor Agonists in Patients with Chronic Insomnia Disorder

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

夏明月

研究负责人:

陈云飞

Applicant:

Xia Ming-yue

Study leader:

Chen Yun-fei

申请注册联系人电话:

Applicant telephone:

+86 15628926229

研究负责人电话:

Study leader's telephone:

+86 18930568221

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xmyue777@163.com

研究负责人电子邮件:

Study leader's E-mail:

icyf1968@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区甘河路110号

研究负责人通讯地址:

上海市虹口区甘河路110号

Applicant address:

110 Ganhe Road Hongkou District Shanghai China

Study leader's address:

110 Ganhe Road Hongkou District Shanghai China

申请注册联系人邮政编码:

Applicant postcode:

200437

研究负责人邮政编码:

Study leader's postcode:

200437

申请人所在单位:

上海中医药大学附属岳阳中西医结合医院

Applicant's institution:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine.Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025-059

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

上海中医药大学附属岳阳中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine;Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/3/26 0:00:00

伦理委员会联系人:

殷从全

Contact Name of the ethic committee:

Congquan Yin

伦理委员会联系地址:

上海市虹口区甘河路110号上海中医药大学附属岳阳中西医结合医院行政楼102室

Contact Address of the ethic committee:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine; Shanghai University of Traditional Chinese Medicine; 110 Ganhe Road; Hongkou District; Shanghai; China

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-65161782-8122

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yyyyllwyh@163.com

研究实施负责(组长)单位:

上海中医药大学附属岳阳中西医结合医院

Primary sponsor:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine;Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市虹口区甘河路110号上海中医药大学附属岳阳中西医结合医院

Primary sponsor's address:

110 Ganhe Road Hongkou District Shanghai China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院

具体地址:

上海市虹口区甘河路110号上海中医药大学附属岳阳中西医结合医院

Institution
hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine;Shanghai University of Traditional Chinese Medicine

Address:

110 Ganhe Road, Hongkou District, Shanghai, China

经费或物资来源:

自筹经费

Source(s) of funding:

Self-financing

研究疾病:

慢性失眠

研究疾病代码:

Target disease:

Chronic Insomnia Disorder

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

1. 探究针刺在慢性失眠患者中辅助减停BZRAs药物的有效性和安全性,以及针刺在辅助减停BZRAs药物过程中对慢性失眠患者睡眠质量、日间功能、减药反应的影响。 2. 探究长期使用BZRAs对慢性失眠患者的中枢功能联系与脑区代谢相关性,揭示针刺对慢性失眠患者辅助减停BZRAs的中枢影像学机制。

Objectives of Study:

1.To investigate the efficacy and safety of acupuncture as an adjunctive therapy in tapering benzodiazepine receptor agonists (BZRAs) in patients with chronic insomnia and to evaluate its effects on sleep quality daytime functioning and medication tapering response.2.To explore the correlation between long-term use of BZRAs and central functional connectivity and brain region metabolism in patients with chronic insomnia and to elucidate the central neuroimaging mechanisms by which acupuncture aids in the tapering of BZRAs.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.年龄≥18岁且≤75岁,性别不限;2.符合ICSD-3TR中慢性失眠诊断标准;3.服用BZRAs药物状态下,ISI≤21分;4.接受苯二氮卓类受体激动剂治疗慢性失眠超过6个月,服药时间超过50%,近2周服药频率≥3晚/周;5.服用的药物种类为《中国成人失眠诊断与治疗指南(2023版)》中推荐的BZRAs药物,包括BZDs、non-BZDs和新型苯二氮䓬受体激动剂,每次服用剂量不超过指南推荐的最大剂量;6.自我报告过去至少一次自行停用BZRA失败的经历;7.患者本人有BZRA药物减量的意愿;8.3个月内未接受过任何形式的针刺治疗;9.自愿参加本课题并遵守方案要求,签署知情同意书。

Inclusion criteria

1.Age between 18 and 75 years inclusive with no gender restrictions;2.Meeting the chronic insomnia diagnostic criteria as defined in the ICSD-3TR;3.Insomnia Severity Index (ISI) score of ≤21 while on BZRAs medication;4.Undergoing benzodiazepine receptor agonist treatment for chronic insomnia for more than 6 months with medication adherence over 50% and a frequency of at least 3 nights per week in the past 2 weeks;5.Using BZRAs medications recommended by the "Chinese Guideline for the Diagnosis and Treatment of Adult Insomnia (2023 Edition)" including benzodiazepines non-benzodiazepines and novel benzodiazepine receptor agonists with each dosage not exceeding the maximum recommended in the guideline;6.Self-reported history of at least one unsuccessful attempt to discontinue BZRAs;7.A personal desire to reduce BZRAs medication;8.No acupuncture treatment received in any form within the past 3 months;9.Willingness to participate in the study comply with the protocol requirements and sign the informed consent form.

排除标准:

1.经PSG检测,AHI指数≥15次/小时,和/或周期性肢体运动指数伴随觉醒≥15次/小时,和/或发现REM睡眠肌电失迟缓现象,和/或梦境演绎行为。2.筛选期前2周及整个研究期间,有倒班工作安排,或前往2个以上时区外的地方出行者;3.筛选期前2周及整个研究期间,服用抗焦虑抑郁药物、抗精神病药物、褪黑素及褪黑素受体激动剂者;4.一年内有酒精或物质使用障碍史;5.严重的精神障碍史(如双向情感障碍、重度抑郁等);6.严重的心、肝、肾以及血液、呼吸系统等疾病;未控制的传染性疾病;7.畏针、晕针,或所选穴位附近有感染、炎症、疤痕、损伤而无法接受针灸治疗者;8.妊娠期或哺乳期妇女;9.研究者认为有不适合纳入的情况;10.3个月内参加过干预性临床试验者。

Exclusion criteria:

1.Apnea-Hypopnea Index (AHI) of 15 or more events per hour as detected by polysomnography (PSG) and/or periodic limb movement index with arousal of 15 or more events per hour and/or evidence of REM sleep without atonia and/or dream enactment behaviors.2. Shift work schedule or travel across more than two time zones during the two weeks prior to screening or at any time during the study period.3.Use of anxiolytics antidepressants antipsychotics melatonin or melatonin receptor agonists during the two weeks prior to screening or at any time during the study period.4History of alcohol or substance use disorder within the past year.5.History of severe psychiatric disorders (e.g. bipolar disorder major depression).6.Severe cardiovascular hepatic renal hematologic or respiratory diseases; uncontrolled infectious diseases.7.Needle phobia or conditions such as infection inflammation scarring or injury near selected acupuncture points that would prevent acupuncture therapy.8.Pregnant or breastfeeding women.9.Any condition that the investigator deems unsuitable for the study.10.Participation in any interventional clinical trial within the past 3 months.

研究实施时间:

Study execute time:

From 2025-05-28

To      2026-09-30

征募观察对象时间:

Recruiting time:

From 2025-06-01

To      2026-06-30

干预措施:

Interventions:

组别:

假针刺组

样本量:

83

Group:

Comfort needle group

Sample size:

干预措施:

假针刺联合常规减量

干预措施代码:

Intervention:

Comfort Acupuncture Combined with Usual Tapering Group

Intervention code:

组别:

常规减量组

样本量:

83

Group:

Control group

Sample size:

干预措施:

常规减量

干预措施代码:

Intervention:

Usual tapering group

Intervention code:

组别:

针刺组

样本量:

83

Group:

Treatment group

Sample size:

干预措施:

针刺联合常规减量

干预措施代码:

Intervention:

Acupuncture Combined with Usual Tapering Group

Intervention code:

样本总量 Total sample size : 249

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江省中医院

单位级别:

三级甲等

Institution/hospital:

Zhejiang Provincial Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

四川省人民医院

单位级别:

三级甲等

Institution/hospital:

Sichuan Provincial People's Hospita

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海中医药大学附属岳阳中西医结合医院

单位级别:

三级甲等

Institution/hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine;Shanghai University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

单位级别:

三级甲等

Institution/hospital:

Huashan Hospital Fudan University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

青浦区中医医院

单位级别:

二级甲等

Institution/hospital:

Qingpu District Hospital of Traditional Chinese Medicine

Level of the institution:

Grade 2A Hospital

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

嘉定区中医医院

单位级别:

二级甲等

Institution/hospital:

Jiading District Hospital of Traditional Chinese Medicine

Level of the institution:

Grade 2A Hospital

测量指标:

Outcomes:

指标中文名:

PHQ-9健康问卷

指标类型:

次要指标

Outcome:

Patient Health Questionaire-9

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

共识睡眠日记

指标类型:

次要指标

Outcome:

Consensus sleep diary

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

次要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Epworth 嗜睡量表

指标类型:

次要指标

Outcome:

Epworth Sleepiness Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

广泛性焦虑量表

指标类型:

次要指标

Outcome:

Generalized Anxiety Disorder 7-item

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

针灸期待程度量表

指标类型:

次要指标

Outcome:

Acupuncture Expectancy Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

BZRAs药物的减药率

指标类型:

次要指标

Outcome:

the tapering rate of BZRAs medications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疲劳严重指数量表

指标类型:

次要指标

Outcome:

Fatigue Severity Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

客观睡眠质量

指标类型:

次要指标

Outcome:

Objective sleep architecture metrics

Type:

Secondary indicator

测量时间点:

测量方法:

多导睡眠监测

Measure time point of outcome:

Measure method:

polysomnography

指标中文名:

盲法评价

指标类型:

次要指标

Outcome:

blind assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

失眠严重指数

指标类型:

次要指标

Outcome:

Insomnia Severity Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中枢影像学指标

指标类型:

附加指标

Outcome:

Central Nervous System Imaging Indicators

Type:

Additional indicator

测量时间点:

测量方法:

该指标仅在主中心纳入的临床受试者中进行,另外增加两个对照组,分别为健康对照组及未服用BZRAs的慢性失眠对照组各20例,进行磁共振检测,包括静息态磁共振和磁共振波谱成像

Measure time point of outcome:

Measure method:

In addition to the patients at the main center ,two control groups will be added: a healthy control group and a chronic insomnia control group not taking BZRAs with 20 cases in each group for magnetic resonance imaging (MRI) assessments including fMRI and MRS

指标中文名:

苯二氮卓类安眠药戒断量表

指标类型:

次要指标

Outcome:

Benzodiazepine Hypnotics Withdrawal Symptom Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

6周治疗结束后停药的有效率

指标类型:

主要指标

Outcome:

The efficacy of drug withdrawal after 6 weeks of treatment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

药物渴求视觉模拟量表

指标类型:

次要指标

Outcome:

Visual Analogue Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine specimen

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究采用中央区组随机化设计,根据1:1:1的比例随机分配至针刺组、假针刺组和常规减量组。由独立的第三方统计人员通过统计学软件生成随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

The study adopted a central block randomization design and the patients were randomly assigned to the acupuncture group sham acupuncture group and conventional reduction group in a ratio of 1:1:1. An independent third-party statistician generated the random sequence using statistical software.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集采用病例记录表的形式记录,数据管理使用Redcap数据管理系统。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection was carried out using case report forms and data management was conducted using the REDCap data management system.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above